pinkslipjunkie
12 시간 전
No I found it, R/S has been voted in...after looking again in the 10Q a little harder....and just because it hasn't been activated on Dec 2 that it won't happen...could be any day now until January 15, 2025...they may hold off as long as they can before their 180 day extension is up to become compliant again.
8-K about the compliance 180 days: https://www.otcmarkets.com/filing/html?id=17917292&guid=T8Y-kWV46v3Th3h
10-Q filing: https://www.otcmarkets.com/filing/html?id=17988358&guid=T8Y-kWV46v3Th3h
NOTE 12 – Subsequent Events
On October 1, 2024, the Company’s Board of Directors granted Directors and Officers options to purchase up to 4.5 million shares of common stock for $0.10 per share. The grants have various vesting conditions, including time-based and performance-based terms. Additionally, on October 1, 2024, the exercise price of all other outstanding options granted under the 2024 Plan was adjusted to $0.10 per share, with all other terms of the original grant to remain without adjustment.
On October 23, 2024, the trading price for CERo common stock closed under $0.10 and was the tenth consecutive trading day to do so. On October 24, 2024, the Company received letter from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, because its Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days, it was no longer eligible to rely upon the 180-day cure period that commenced when the Company received notice in July 2024 that the closing bid price was below $1.00 for ten consecutive trading days and was scheduled to expire on January 15, 2025. In addition, on October 30, 2024, the Company received a letter from the staff at Nasdaq notifying the Company that it had not regained compliance with the continued listing requirement to maintain a minimum market value of $50,000,000 for its listed securities within the 180-day compliance period granted by Nasdaq in May 2024. Each such deficiency results in the commencement of delisting proceedings. However, the Company has requested a hearing from Nasdaq and plans to submit a plan to regain compliance with the listing requirements at such hearing.
On November 8, 2024, the Company consummated a purchase agreement with Keystone pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $20.6 million of shares of Common Stock, subject to certain market conditions. The price of the shares purchased by Keystone under the ELOC is 90% of various volume-weighted average price (“VWAP”) and closing price-based formulae, and requires a waiver, should the selling price be below $0.01 per share.
On November 11. 2024, the Company’s stockholders approved a reverse stock split ranging from 1:25 to 1:150. On November 15, 2024, the Board of Directors authorized a reverse stock split ratio of 1:40, such reverse split is anticipated to be effective on or about December 2, 2024. Although such reverse stock split is expected to enable regaining compliance with the Bid Price Requirement, it is not intended to contribute to regaining compliance with the other Requirements.
1-1 is 4
4 주 전
The President-elect has said he wants Robert F. Kennedy Jr. to be part of his health care team, and psychedelics are at the top of a list of things, including raw milk, chelating compounds and sunshine, Kennedy alleges the Food and Drug Administration is keeping away from Americans. By ERIN SCHUMAKER, DANIEL PAYNE, RUTH READER and CARMEN PAUN 11/11/2024 02:00 PM EST
Invest-in-America
1 월 전
CERO: More by "Copilot", regarding the DIFFERENCE between CERO's (fluff-news) "Animal MODEL", vs. legitimate & substantive "Animal STUDIES" ---
"However, can such a Human Pharma research company produce an "ANIMAL MODEL" without having conducted any actual "ANIMAL STUDIES"? I.e., can said company merely be referring to their THEORETICAL concepts for FUTURE actual animal STUDIES & EXPERIMENTS, without having acutally done such studies, etc.? Yes, a pharmaceutical company can indeed refer to an "animal model" in a theoretical context without having conducted actual animal studies. They might outline the animal model they intend to use based on existing knowledge or previous research. This can include describing the species, genetic modifications, or other characteristics that make the animal suitable for studying a particular disease.However, to claim progress or make definitive statements about the efficacy or safety of a drug, actual animal studies and experiments are necessary. These studies provide the empirical data needed to move forward in the drug development process, including eventual human trials. So, while a company can theoretically discuss their planned animal models, the actual validation of those models requires conducting the animal studies. Does that help clarify things for you?"
Invest-in-America
1 월 전
CERO: Below is Bing's "Copilot" for your EDIFICATION regarding this conspicuously-SCAMMING, stinky pinky "company" ---
"What was the name of the influential 'health care' movement of the 20th Century that advocated the consumption of tiny doses of well-known POISONS & TOXIC METALS LIKE LEAD as a cure for all manner of deadly diseases? The influential health care movement you're referring to is likely Homeopathy. Developed in the late 18th century by Samuel Hahnemann, Homeopathy is based on the principle of 'like cures like' and the use of highly diluted substances to treat various ailments. While modern Homeopathy typically uses extremely diluted substances, some historical practices involved the use of tiny doses of known poisons and toxic metals, believing that these could stimulate the body's healing processes. Homeopathy remains a controversial topic in the medical community, with debates about its efficacy and scientific basis. Do you have any specific interest in homeopathy or its history?"